14 October 2025 – Sydney, Australia | Nexsen Limited (ASX:NXN), an Australian nano-biotechnology company developing a next-generation point-of-care diagnostic platform, has today commenced trading on the Australian Securities Exchange (ASX) following a successful $8 million capital raising as part of its Initial Public Offering (IPO).
The capital raised in the IPO will accelerate the development and commercialisation of Nexsen's proprietary biosensing platform and resulting suite of diagnostic products across human health, biosecurity, and ag-tech; with an initial focus on its flagship product for Group B Streptococcus (GBS), GBS Rapid Sensor.
Nexsen's diagnostics platform, developed in collaboration with RMIT University's Sir Ian Potter NanoBioSensing Facility, seeks to address significant unmet needs in critical markets across human health, agriculture, and biosecurity. The Company's vision is for every individual, globally, to benefit from at least one of its tests in their lifetime.
Flagship Product: GBS Rapid Sensor
The GBS Rapid Sensor provides rapid, lab-grade accuracy for the detection of Group B Streptococcus in expectant mothers, which is a major cause of infant morbidity and mortality, stillbirth, and other complications around the globe. Unlike traditional lab-based tests, Nexsen's sensor enables timely diagnosis at the point of labour, offering a significant advance in primary healthcare through faster intervention and better clinical management, whilst mitigating the potential to miss ideal windows for detection.
The GBS Rapid Sensor technology is backed by a $7.7 million Cooperative Research Centres Projects (CRC-P) grant from the Australian Government. The product is planned to commence clinical trials in Q4 of CY2025.
Nexsen's Executive Chairman, Reece O'Connell, commented:
"I am excited to be leading Nexsen at its ASX listing today.
Nexsen was founded with a bold and ambitious purpose to provide accurate, affordable, timely and accessible testing of diseases and threats that are currently constrained by lab-based systems. Too often, critical health decisions are delayed or compromised because diagnostics rely on slow and costly laboratory systems.
Our biosensor platform was developed to revolutionise diagnostic testing by delivering laboratory-grade accuracy in a rapid, portable format. We have the potential to transform healthcare by providing a new generation of diagnostics that are faster, more accessible, and capable of reaching patients and communities worldwide.
Our strategic vision is for every person, globally, to benefit from at least one of our tests in their lifetime."
Pipeline and Broader Applications
Beyond GBS, Nexsen is advancing diagnostic solutions for:
Kidney Disease: Rapid diagnostics for subsets of Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI), targeting early-stage detection and monitoring in critical settings like ICUs and even at home.
Biosecurity and Agricultural Technology: Diagnostic tools for detecting plant pathogens like Xylella and Huanglongbing, as well as Bovine Mastitis in cattle, aiming to mitigate billions in potential agricultural losses.
Scientific and Institutional Support
Nexsen's platform stems from a long-standing collaborative relationship with RMIT University, led by globally recognised nanobiotechnology expert Professor Vipul Bansal. Professor Bansal also now serves as Chief Innovation Officer of Nexsen and chairs the Company's Advisory Board. RMIT University is also a shareholder in the Company.
The Company has also secured further research funding, including:
$1.6 million ARC-supported development for biosecurity diagnostics
$1.6 million for the Bovine Mastitis project under the ARC Research Hub for Molecular Biosensors at Point-of-Use (MOBIUS)
Alpine Capital acted as lead manager for Nexsen's initial public offering.
For corporate
